Correction Notice: Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study

DOI: https://doi.org/10.1097/HS9.0000000000000986

2023-11-02

HemaSphere

Abstract:[This corrects the article DOI: 10.1097/HS9.0000000000000942.].

What problem does this paper attempt to address?

Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China: Erratum

Zhongqing Zou,Tingting Guo,Jian Cui,Wenjiao Tang,Yan Li,Fangfang Wang,Tian Dong,Yunfan Yang,Yan Feng,Matthew Ho,Li Zhang,Ling Pan,Ting Niu

DOI: https://doi.org/10.7150/jca.79561

IF: 3.9

2022-01-01

Journal of Cancer

Abstract:[This corrects the article DOI: 10.7150/jca.53209.].

oncology
Erratum: Palumbo A, Bringhen S, Mateos M-V, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068-2074

DOI: https://doi.org/10.1182/blood-2016-07-727081

IF: 20.3

2016-08-18

Blood

Abstract:[This corrects the article DOI: 10.1182/blood-2014-12-615187.].
Correction Notice: Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

DOI: https://doi.org/10.1097/HS9.0000000000000987

2023-10-31

HemaSphere

Abstract:[This corrects the article DOI: 10.1097/HS9.0000000000000907.].
Erratum: Sequential treatment escalation improves survival in patients with Waldenstrom macroglobulinemia

DOI: https://doi.org/10.1097/BS9.0000000000000185

2024-03-07

Abstract:[This corrects the article DOI: 10.1097/BS9.0000000000000179.].
Correction Notice: Impact of T-cell Receptor Status on Mutational Landscape and Outcome in T-ALL

DOI: https://doi.org/10.1097/HS9.0000000000000980

2023-10-04

HemaSphere

Abstract:[This corrects the article DOI: 10.1097/HS9.0000000000000871.].
Erratum: Richardson PG, Hungria VTM, Yoon S-S, et al. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016;127(6):713-721

DOI: https://doi.org/10.1182/blood-2016-05-717777

IF: 20.3

2016-06-30

Blood

Abstract:[This corrects the article DOI: 10.1182/blood-2015-09-665018.].
Correction: Srinivasan Rajsri et al. Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection. Cancers 2023, 15, 2866

Kritika Srinivasan Rajsri,Nainita Roy,Sohini Chakraborty

DOI: https://doi.org/10.3390/cancers16050954

2024-02-28

Cancers

Abstract:Cancers, Vol. 16, Pages 954: Correction: Srinivasan Rajsri et al. Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection. Cancers 2023, 15, 2866 Cancers doi: 10.3390/cancers16050954 Authors: Kritika Srinivasan Rajsri Nainita Roy Sohini Chakraborty In the original publication [...]

oncology
Erratum: Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009;114(10):2051-2059

DOI: https://doi.org/10.1182/blood-2016-06-723056

IF: 20.3

2016-07-28

Blood

Abstract:[This corrects the article DOI: 10.1182/blood-2008-10-184143.].
Correction to "Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up"

DOI: https://doi.org/10.1002/hem3.118

2024-07-22

HemaSphere

Abstract:[This corrects the article DOI: 10.1002/hem3.89.].
Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data

Quanfeng Zhao,Pan Ma,Peishu Fu,Jiayu Wang,Kejing Wang,Lin Chen,Yang Yang

DOI: https://doi.org/10.3389/fphar.2022.990048

IF: 5.6

2022-08-11

Frontiers in Pharmacology

Abstract:[This corrects the article DOI: 10.3389/fphar.2022.912256.].

pharmacology & pharmacy
Erratum: Kini Bailur J, Mehta S, Zhang L, et al. Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy. Blood Adv. 2017;1(25):2343-2347

DOI: https://doi.org/10.1182/bloodadvances.2017015438

2018-01-09

Abstract:[This corrects the article DOI: 10.1182/bloodadvances.2017012732.].
Corrigendum to "Gene mutations in newly diagnosed multiple myeloma patients detected by next-generation sequencing technology" [ Cancer Pathog Ther. 2024;2:205-211]

Yutong Wang,Mengzhen Wang,Bin Chu,Minqiu Lu,Lei Shi,Shan Gao,Yuan Chen,Qin Yan,Na Ji,Li Bao

DOI: https://doi.org/10.1016/j.cpt.2024.09.002

2024-09-14

Abstract:[This corrects the article DOI: 10.1016/j.cpt.2023.12.004.].
Erratum to "Additional biomarkers for pathological complete response in triple negative breast cancer"

DOI: https://doi.org/10.1177/17588359241290373

2024-10-21

Abstract:[This corrects the article DOI: 10.1177/17588359241267148.].
Erratum: Chen Z, Orlowski RZ, Wang M, Kwak L, McCarty N. Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood. 2014;123(14):2204-2208

DOI: https://doi.org/10.1182/blood-2016-03-707646

IF: 20.3

2016-06-02

Blood

Abstract:[This corrects the article DOI: 10.1182/blood-2013-07-517136.].
Corrigendum to "Long recurrence-free survival of localized rectal melanoma after abdominoperineal resection in comparison to partial excision and highlighting the place of immunotherapy: A case report."

DOI: https://doi.org/10.1177/20542704241260192

2024-06-02

JRSM Open

Abstract:[This corrects the article DOI: 10.1177/20542704221148059.].
Erratum: Zeiser R, Blazar BR. Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation? Blood. 2016;127(25):3117-3126

DOI: https://doi.org/10.1182/blood-2016-07-730580

IF: 20.3

2016-09-08

Blood

Abstract:[This corrects the article DOI: 10.1182/blood-2016-02-699082.].
Correction: Corrigendum: Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma

Terri A Addona,Susan E Abbatiello,Birgit Schilling,Steven J Skates,D R Mani,David M Bunk,Clifford H Spiegelman,Lisa J Zimmerman,Amy-Joan L Ham,Hasmik Keshishian,Steven C Hall,Simon Allen,Ronald K Blackman,Christoph H Borchers,Charles Buck,Helene L Cardasis,Michael P Cusack,Nathan G Dodder,Bradford W Gibson,Jason M Held,Tara Hiltke,Angela Jackson,Eric B Johansen,Christopher R Kinsinger,Jing Li,Mehdi Mesri,Thomas A Neubert,Richard K Niles,Trenton C Pulsipher,David Ransohoff,Henry Rodriguez,Paul A Rudnick,Derek Smith,David L Tabb,Tony J Tegeler,Asokan M Variyath,Lorenzo J Vega-Montoto,Åsa Wahlander,Sofia Waldemarson,Mu Wang,Jeffrey R Whiteaker,Lei Zhao,N Leigh Anderson,Susan J Fisher,Daniel C Liebler,Amanda G Paulovich,Fred E Regnier,Paul Tempst,Steven A Carr

DOI: https://doi.org/10.1038/nbt0909-864b

IF: 46.9

2009-01-01

Nature Biotechnology

Abstract:Nat. Biotechnol. 27, 633–641 (2009); published online 28 June 2009; corrected after print 9 September 2009 In the version of this article initially published, the following acknowledgment was inadvertently left out: “The UCSF CPTAC team gratefully acknowledges the support of the Canary Foundation for providing funds to purchase a 4000 QTRAP mass spectrometer.
Erratum to: Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma

Umair Munawar,Johanna Theuersbacher,Maximilian J. Steinhardt,Xiang Zhou,Seungbin Han,Silvia Nerreter,Cornelia Vogt,Shilpa Kurian,Thorsten Keller,Ann-Katrin Regensburger,Eva Teufel,Julia Mersi,Max Bittrich,Franziska Seifert,Malik S. Haider,Leo Rasche,Jost Hillenkamp,Hermann Einsele,Daniel Kampik,K. Martin Kortüm,Johannes M. Waldschmidt

DOI: https://doi.org/10.3324/haematol.2024.285821

2024-11-05

Haematologica

Abstract:In the original version of our article, "Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma", 1 Table 1 contained a duplicated data column. The authors apologize for this error and state that this does not change the scientific conclusions of the study. The corrected table is shown below.

hematology
Corrigendum to "Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy" [ Kidney International Reports Volume 6, Issue 4, April 2021, Pages 1183-1188]

Maxime Teisseyre,Sonia Boyer-Suavet,Marion Crémoni,Vesna Brglez,Vincent Esnault,Barbara Seitz-Polski

DOI: https://doi.org/10.1016/j.ekir.2024.05.020

2024-05-23

Abstract:[This corrects the article DOI: 10.1016/j.ekir.2021.01.022.].
Correction Notice – Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study

DOI: https://doi.org/10.1097/hs9.0000000000000973

2023-10-19

HemaSphere

Abstract:[This corrects the article DOI: 10.1097/HS9.0000000000000320.].

Correction Notice: Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study

Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China: Erratum

Erratum: Palumbo A, Bringhen S, Mateos M-V, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068-2074

Correction Notice: Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

Erratum: Sequential treatment escalation improves survival in patients with Waldenstrom macroglobulinemia

Correction Notice: Impact of T-cell Receptor Status on Mutational Landscape and Outcome in T-ALL

Erratum: Richardson PG, Hungria VTM, Yoon S-S, et al. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016;127(6):713-721

Correction: Srinivasan Rajsri et al. Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection. Cancers 2023, 15, 2866

Erratum: Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009;114(10):2051-2059

Correction to "Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up"

Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data

Erratum: Kini Bailur J, Mehta S, Zhang L, et al. Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy. Blood Adv. 2017;1(25):2343-2347

Corrigendum to "Gene mutations in newly diagnosed multiple myeloma patients detected by next-generation sequencing technology" [ Cancer Pathog Ther. 2024;2:205-211]

Erratum to "Additional biomarkers for pathological complete response in triple negative breast cancer"

Erratum: Chen Z, Orlowski RZ, Wang M, Kwak L, McCarty N. Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood. 2014;123(14):2204-2208

Corrigendum to "Long recurrence-free survival of localized rectal melanoma after abdominoperineal resection in comparison to partial excision and highlighting the place of immunotherapy: A case report."

Erratum: Zeiser R, Blazar BR. Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation? Blood. 2016;127(25):3117-3126

Correction: Corrigendum: Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma

Erratum to: Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma

Corrigendum to "Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy" [ Kidney International Reports Volume 6, Issue 4, April 2021, Pages 1183-1188]

Correction Notice – Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study